Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression

Drug resistance, a major obstacle to successful cancer chemotherapy, frequently occurs in recurrent or metastatic breast cancer and results in poor clinical response. Fulvestrant is a new type of selective estrogen receptor (ER) downregulator and a promising endocrine therapy for breast cancer. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yuan, Jiang, Donghai, Sui, Meihua, Wang, Xiaojia, Fan, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355712/
https://www.ncbi.nlm.nih.gov/pubmed/28000875
http://dx.doi.org/10.3892/or.2016.5315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355712/
https://www.ncbi.nlm.nih.gov/pubmed/28000875
http://dx.doi.org/10.3892/or.2016.5315

Ejemplares similares